OXB Completes Full Acquisition of US Subsidiary for Gene Therapy Expansion

• OXB has acquired the remaining 10% stake in its US subsidiary from Q32 Bio, achieving full ownership.

• The Bedford, MA facility is fully integrated into OXB’s global CDMO network, supporting AAV and lentiviral vector manufacturing.

OXB, a global cell and gene therapy CDMO, has announced the acquisition of the remaining 10% stake in its US subsidiary, OXB US LLC, from Q32 Bio. This move brings the company’s ownership of the US operation to 100%, as previously planned.

The transaction follows the exercise of a call option by OXB US Inc. on 1 March 2025, as outlined in OXB’s Preliminary Results published in April. The stake was originally held by Homology Medicines, Inc., which merged with Q32 Bio in 2024. With the completion of this transfer, OXB US LLC is now a wholly owned subsidiary of OXB.

Established in Bedford, Massachusetts in 2022, the site was created as a dedicated AAV manufacturing and innovation hub. It has since been integrated into the company’s broader global operations. In 2024, OXB successfully transferred its lentiviral platform to the US facility, which spans 96,000 ft² and supports multiple vector manufacturing programmes.

Commenting on the development, Dr Frank Mathias, Chief Executive Officer of OXB, said: “The progression to full ownership of our US business marks an important step for OXB. It strengthens our position in a key market and helps meet growing demand for high-quality vector manufacturing.”

OXB’s presence in the US, alongside facilities in the UK and France, reinforces its capabilities in AAV and lentiviral vector-based therapies. The company’s CDMO services span the full development cycle, from early-stage projects to commercial manufacturing.